multiple sclerosis

[Nature Reviews Neurology] The authors provide an overview of the involvement of astrocytes and microglia at major sites of pathology in progressive multiple sclerosis.

[Nature Reviews Drug Discovery] The authors highlight general mechanisms of astrocyte regulation and their potential as therapeutic targets, including drugs that alter astrocyte metabolism, and therapies that target transporters and receptors on astrocytes.

[Neuron] Scientists found that immune genes exhibit a primed chromatin state in single mouse and human oligodendroglia in a non-disease context, compatible with transitions to immune-competent states in multiple sclerosis.

[Clinical Science] Scientists investigated the potential effects of solid lipid nanoparticles containing dimethyl fumarate, administered by inhalation on the clinical signs, central nervous system inflammatory response, and lung function changes in mice with experimental autoimmune encephalomyelitis.

[Journal of Immunology] The authors observed significantly fewer LAG-3+ CD4 and CD8 T cells from subjects with relapsing-remitting multiple sclerosis and type 1 diabetes.

[Emerald Health Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] Emerald Health Pharmaceuticals, Inc. received clearance of its Investigational New Drug (IND) application by the FDA to begin enrolling patients in its Phase IIa clinical trial of EHP-101 for certain relapsing forms of multiple sclerosis (MS), specifically relapsing-remitting MS and active secondary progressive MS.